Nurix Therapeutics is trading 4.76% down at $25.01 after a broad risk-off session tied to escalating U.S.-Iran tensions, oil above $100 per barrel, and weaker equity futures.
- The S&P 500 is down 0.61% and Nasdaq Composite is down 1.32%, creating especially strong pressure on risk-sensitive biotechnology stocks.
- No clear company-specific announcement explains the September 10, 2026 decline; the latest investor-relations update lists scheduled events and prior milestones.